Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SI-BONE, Inc. (SIBN)

SI-BONE raises 2026 revenue guidance to $231M-$233M as Q2 revenue rises 15.2%

Positive Impact 4 of 5 earnings Written later

SI-BONE reported second-quarter 2026 worldwide revenue of $56.0 million, up 15.2% from a year earlier, and a net loss of $4.1 million, narrowed from $6.2 million. The company raised its 2026 worldwide revenue guidance to $231 million to $233 million from $230 million to $233 million, and it kept gross margin guidance at about 79%. For shareholders, the filing shows faster sales growth, a smaller loss and a higher low end of the revenue forecast.

Key points

  • Q2 2026 worldwide revenue was $56.0 million, up 15.2%; U.S. revenue was $53.2 million, up 14.7%.
  • Net loss narrowed to $4.1 million, or $0.09 per diluted share, from $6.2 million, or $0.14, a year earlier.
  • 2026 revenue guidance is now $231 million to $233 million, implying growth of about 15% to 16%, versus the prior $230 million to $233 million.
  • Cash and equivalents were $145.9 million as of June 30, 2026, up from $144.7 million on March 31, 2026.

The filing

CompanySI-BONE, Inc. (SIBN)
Form8-K, current report
Filed with the SECAug 3, 2026, 4:11 PM ET
Accession number0001459839-26-000066

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.